Endovascular Engineering ENGULF Study

Not Applicable

Recruiting

• Conditions: Pulmonary Embolism

• Registration Number: NCT05597891
• Lead Sponsor: Endovascular Engineering

Brief Summary

Evaluation of initial safety and clinical feasibility of the Hēlo PE Thrombectomy System for thrombectomy in acute submassive pulmonary embolism (PE).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-10-14
• Study First Submitted QC: 2022-10-24
• Study First Posted: 2022-10-28
• Study Start: 2023-01-12
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-13
• Last Update Posted: 2024-12-17
• Primary Completion: 2025-08-31
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 181

Inclusion Criteria

Patients must meet ALL of the following criteria to be eligible for participation in the study:

1. *Patient is > 18 and < 90 years old
2. *Clinical signs and symptoms consistent with acute submassive PE with duration ≤ 14 days, as determined by the Investigator
3. (*)CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
4. (*)RV/LV ratio of ≥ 0.9 (Enrollment qualification assessment based on Investigator's interpretation of RV/LV ratio at baseline)
5. *Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
6. *Heart rate < 130 BPM prior to procedure
7. *Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment
8. Patient signs a written Informed Consent form to participate in the study, prior to any study mandated procedures

Exclusion Criteria

Patients must be EXCLUDED from participation in this study if ANY of the following criteria are met:

1. *Acute massive PE at presentation
2. *Prior PE within last 6 months
3. *Thrombolytic use within 30 days of baseline CTA
4. *Pulmonary hypertension with peak pulmonary artery systolic pressure > 70 mmHg by right heart catheterization
5. *Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
6. *FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%
7. *Hematocrit < 28% (NOTE: hematocrit required within 24 hours of index procedure)
8. *Platelets < 100,000/μL
9. *Serum creatinine > 1.8 mg/dL
10. *International normalized ratio (INR) > 3
11. *aPTT (or PTT) > 50 seconds on no anticoagulation
12. *Major trauma < 14 days
13. *Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months
14. *Cardiovascular or pulmonary surgery within last 7 days
15. *Life expectancy less than 1 year due to advanced malignancy, as determined by the investigator at the time of enrollment
16. *Known bleeding diathesis or coagulation disorder
17. *Known left bundle branch block
18. *History of severe pulmonary arterial hypertension
19. *History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
20. *History of uncompensated heart failure
21. *History of underlying lung disease that is oxygen dependent
22. *Presence of IVC filter and or iliocaval stents
23. *History of heparin-induced thrombocytopenia (HIT)
24. *Any contraindication to systemic or therapeutic doses of heparin or anticoagulants
25. *Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
26. *Known allergy to any device component
27. (*)Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominately chronic clot or non-clot embolus)
28. *Life expectancy of < 90 days, as determined by Investigator
29. *Female who is pregnant or nursing
30. *Current participation in another investigational drug or device treatment study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Primary Performance Objective	48 hours following the procedure	Clinical Success, defined as the reduction in RV/LV ratio from baseline to 48 hours (+/- 24 hours, or discharge, whichever occurs first) as assessed by CTA
Primary Safety Objective	48 hours following the procedure	Composite device-related Major Adverse Event (MAE) rate, defined as any of the following events within 48 hours (+/- 24 hours) of the procedure: * Death; * Life-threatening, disabling or major bleeding as defined by VARC-2; * Serious adverse events, including, clinical deterioration, pulmonary vascular injury, and cardiac injury

Trial Locations

Locations (19)

Huntington Hospital; 🇺🇸 Pasadena, California, United States

Baptist Health Research Institute; 🇺🇸 Jacksonville, Florida, United States

TriHealth Hatton Research Institute; 🇺🇸 Cincinnati, Ohio, United States

Baylor Scott & White Research Institute; 🇺🇸 Dallas, Texas, United States

UT Health; 🇺🇸 Houston, Texas, United States

Gundersen Health; 🇺🇸 La Crosse, Wisconsin, United States

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; 🇺🇸 Torrance, California, United States

Torrance Memorial Medical Center; 🇺🇸 Torrance, California, United States

Delray Medical Center; 🇺🇸 Delray Beach, Florida, United States

HCA Florida Memorial Hospital; 🇺🇸 Jacksonville, Florida, United States

Scroll for more (9 remaining)